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Brief summary 
There are only few cases in the literature of light-chain amyloidosis (AL) occurring in parallel to 
sarcoidosis. We present a patient with chronic sarcoidosis, heart failure and severe arrhythmia 
secondary to AL amyloidosis involvement. We highlight the value of cardiovascular magnetic 
resonance to discriminate between different patterns of myocardial infiltration and identify the 
diagnosis of cardiac amyloidosis. 
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Abstract 
 
We describe the case of a 66-year old woman with the extremely rare combination of 
sarcoidosis-amyloidosis (light-chain) and the important role of cardiovascular magnetic 
resonance imaging to differentiate between these two infiltrative diseases. Myocardial 
characterization with T1 mapping can improve disease detection especially in overlap cases 
and possibly obviate the need for cardiac biopsy. 
 
Introduction 
With the use of cardiovascular magnetic resonance imaging (CMR) and accurate myocardial 
tissue characterisation, the aetiology of a variety of cardiomyopathies can be differentiated, 
potentially obviating the need for invasive testing and myocardial tissue biopsy.  
Sarcoidosis and amyloidosis both represent systemic infiltrative diseases associated with 
non-caseating granuloma formation and amyloid deposition respectively, in a range of 
tissues and organs. Although cardiac involvement carries a poor prognosis in both systemic 
amyloidosis and sarcoidosis, specific therapeutic options exist for both pathologies and 
hence accurate identification of the aetiology of the cardiomyopathy is crucial. Late 
gadolinium enhancement (LGE) CMR is useful for the detection of cardiac infiltration, but 
LGE patterns are not always typical and often overlap making the interpretation challenging. 
Myocardial characterization with T1 mapping can improve disease detection especially in 
overlap cases.  
 
Case Presentation 
A 66-year-old woman with long standing active multi-system sarcoidosis on corticosteroid 
and methotrexate therapy presented with cardiac chest pain, non-sustained ventricular 
tachycardia and mildly elevated troponin. Inpatient coronary angiography showed no 
obstructive coronary artery disease. She was referred to our institution for consideration of 
an implantable cardioverter defibrillator (ICD). A CMR was requested prior to the ICD to 
assess for any cardiac sarcoidosis involvement. Anatomical and functional cine CMR images 
showed concentric hypertrophy of the left ventricle (LV) (maximum thickness 17mm), 
normal ejection fraction and mildly dilated atria. Long axis function was reduced for both 
ventricles (MAPSE 7mm, TAPSE 10mm) in keeping with restrictive physiology. In the late 
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phase after gadolinium it proved difficult to null the myocardium (Figure 1) but there was a 
suggestion of heterogeneity in the signal intensity across the myocardium with a prominent 
and dense mid-wall enhancement in the apical septum and basal inferolateral wall. At this 
stage (30 minutes after Gadolinium injection) post-contrast T1 mapping using a high 
resolution 4(1)3(1)2   MOLLI prototype sequence (Siemens WIP 448B) as shown in Figure 2 
was performed on a 1.5T  scanner (Magnetom Avanto
fit
, Siemens Healthcare, Erlangen, 
Germany). This interestingly confirmed abnormal gadolinium kinetics; septal myocardial 
T1=379ms, blood T1=409ms. In particular, the myocardial post-contrast T1 value was lower 
than the post-contrast blood value. This reversed pattern (post-contrast T1 
blood>myocardium) is abnormal and to date has only been described in the amyloid 
population
1
.  As T1 mapping was not part of the routine protocol but was requested upon 
the finding of an unusual LGE pattern, there were no native T1 values to allow calculation of 
ECV. 
Based on the findings of T1 mapping as well as the difficulty to null the myocardium on LGE 
images, a diagnosis of cardiac amyloid in a patient with known systemic sarcoidosis was 
made and further tests to investigate this were organised.  
 
The patient underwent (99m) Tc-3,3-diphosphono-1,2-propanodicarboxylic acid ((99m)Tc-
DPD) scanning and 123I-labeled serum amyloid P component (SAP) scintigraphy. The DPD 
report was negative, , excluding transthyretin based disease
2
.The SAP report was positive 
for a large amyloid load within the liver spleen and kidneys. The absence of heart uptake 
might be explained by the massive accumulation of the tracer in the visceral organs leaving 
no significant amount available for the heart or by the lack of fenestrated endothelium in 
the myocardium.  Overall the technique has a lower diagnostic performance for the heart
3
. 
Serum biochemical investigations showed a lambda light chain in excess of 240mg/L (normal 
range 5.7-26.3mg/L). Fat pad aspirate biopsy showed the presence of amyloid by the 
staining of amorphous material with Congo red (Figures S1-S3). The diagnosis of AL 
amyloidosis with evidence of lambda light chain secreting plasma cell dyscrasia was reached 
and chemotherapy was initiated. 
 
Discussion  
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The combination of sarcoidosis and amyloidosis is extremely rare and has only been 
described in seven cases (5 cases AA and 2 cases AL type) in the literature previously, all 
following myocardial biopsy, heart transplantation or autopsy 
4
.  
 It has been argued that the sarcoidosis-related inflammatory process is implicated in the 
pathogenesis of AA amyloidosis. Long-standing inflammatory diseases are associated with 
increased concentrations of an acute phase reactant—serum amyloid A which is a precursor 
of amyloid AA protein. However, AA amyloidosis shows minimal involvement of the 
myocardium.  
AL amyloidosis on the other hand is associated with plasma cell dyscrasias and shows 
extensive deposition in theheart. Even though the co-existence of AA amyloidosis and active 
sarcoidosis has been reported in 5 cases the relationship between cardiac AL amyloidosis 
and active systemic sarcoidosis as in our case is less well understood.  
Two prior reports describe co-existence of cardiac sarcoidosis and AL amyloidosis, in the 
presence of a plasma cell dyscrasia
4
. 
This is in keeping with a recent meta-analysis that has shown a significant (though 
moderate) association between sarcoidosis and malignancy, including myeloma, likely 
mediated via chronic inflammation or immune system derangement
5
. 
In our case MOLLI T1 mapping was helpful to confirm the initial suspicion raised by the 
conventional CMR of an uncommon combination of sarcoidosis and amyloidosis 
involvement prompting for further invasive investigations. 
 
Conclusion 
To our knowledge, this is the first case reported in the literature where CMR was 
instrumental in the correct identification of cardiac amyloidosis in the setting of systemic 
sarcoidosis and T1 mapping was used for confirmation.  The most likely causes of cardiac 
infiltration in our patient would have been active sarcoidosis or a sarcoidosis-related AA 
amyloidosis. However, a rarer combination was identified with AL amyloidosis and active 
sarcoidosis, challenging Occam’s principle. 
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Figure 1. Panel showing LGE images of the heart showing the difficulty in nulling 
myocardium at different inversion times and time intervals and the abnormal gadolinium 
kinetics.
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Figure 2. Panel A showing 30 minutes post-contrast myocardial T1 value being lower than 
post-contrast blood T1 (panel B). This is paradoxical so early after injection and only been 
reported in amyloid. Hence the suspicion of amyloid was raised in this patient and further 
invasive investigations undertaken which confirmed amyloid. T1 maps analysed by  
Circle CVi
42
, Calgary, Canada 
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